A "merger of equals" that strategically positions PYL and MMJ as a diversified, global, growth-oriented and vertically-integrated MC company, from cultivation of medical cannabis to development and distribution of pharmaceutical and nutraceutical products
- MMJ-PYL's "Farm to Pharma" strategy diversifies the merged group across all key segments of the MC value chain
- Deal consideration (based on PYL's last traded share price of $0.305) of $15.5 million in PYL scrip and an additional $5.185 million in performance shares subject to completion of value creating milestones
- Complementary strategies and asset portfolios to yield significant synergies
- Revenue from sales of a proprietary GMP-produced gastro-resistant Cannabidiol (CBD) pill expected by July 2015
- Near-term license approval for MMJ's Duncan Facility (near Vancouver, BC) under the Marijuana for Medical Purposes Regulations (MMPR) to produce up to 700kgs of MC per annum
- Strong platform set for international growth in both the Canadian and European MC markets
- PYL has sufficient existing funds available to meet the working capital requirements of MMJ until revenues commence, meaning that the transaction does not require an equity raising by PYL